



Raju P. Sardar
B.Com., F.C.A.

R. P. Sardar & Co.
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,
I. C. Colony, Borivali (West), Mumbai - 400 103.
Tel.: +91-22-2893 3556 • Mobile : +91-98212 16687
E-mail : rpsardar@gmail.com

Limited Review Report on Unaudited Quarterly and Year-to-date Standalone Financial results of the company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) regulation, 2015, as amended ("Listing Regulations").

To
The Board of Directors
THEMIS MEDICARE LIMITED

1. *We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **THEMIS MEDICARE LIMITED** ("the Company") for the Quarter ended on 30 September, 2021 and year to date results of the period 01 April, 2021 to 30 September, 2021 ("the Statement").*
2. *This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.*
3. *We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.*
4. *Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies thereon, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.*

For R.P. Sardar & Co.
Chartered accountants
(Firm's Registration No. 109273W)

Raju P. Sardar

Raju P. Sardar
(Proprietor)
(Membership No. 037845)

UDIN - 21037845AAAAPO2021

Place: Mumbai
Date: 12/11/2021





Raju P. Sardar
B.Com., F.C.A.

R. P. Sardar & Co.
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,
I. C. Colony, Borivali (West), Mumbai - 400 103.
Tel.: +91-22-2893 3556 • Mobile : +91-98212 16687
E-mail : rpsardar@gmail.com

Limited Review Report on Unaudited Quarterly and Year-to-date Consolidated Financial results of the company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) regulation, 2015, as amended ("Listing Regulations").

To
The Board of Directors
THEMIS MEDICARE LIMITED

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **THEMIS MEDICARE LIMITED** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and the total comprehensive income of its associates for the quarter ended September 30, 2021 and year to date results for the period from April 01, 2021 to September 30, 2021 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. ('Listing Regulations')*
- 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review*
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.*



We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. *The Statement includes the results of the following entities:*

Subsidiaries

- a. *Carpo Medical Limited (UK)*
- b. *Themis lifestyle Private limited*
- c. *Artemis biotech Limited*

Associates

- a. *Gujarat Themis Biosys Limited*
- b. *Long Island Nutritionals Private Limited*

Associate (Joint Venture)

- a. *Richter Themis Medicare (India) Private Limited*

5. *Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed or that it contains any material misstatement.*

6. *We did not review the financial information of 2 Associates & 1 Joint Venture, whose financial information reflect total assets of Rs.25,104.86 Lakhs as at 30 September, 2021 and total revenues of Rs.5,844.39 Lakhs and Rs.11,603.50 Lakhs, total net Profit after tax of Rs.1,574.57 Lakhs and Rs.3,166.95 Lakhs and total comprehensive income of Rs.-0.77 Lakhs and Rs.-1.54 Lakhs for the quarter ended 30 September, 2021 and for the period from 01 April, 2021 to 30 September, 2021, as considered in the consolidated unaudited financial results.*

7. *One subsidiary which is located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles, generally accepted in the country and which have been audited by other auditor under generally accepted auditing standards applicable in the country. The Company's*



R.P. Sardar & Co.

Chartered Accountants

management has converted the financial statement of such subsidiary located outside India from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affair of such subsidiary located outside India is based on the report of the other auditor and the conversion adjustments prepared by the management of the Company and audited by us.

Our conclusion on the Statement is not modified in respect of the above matter.

**For R.P. Sardar & Co.
Chartered accountants
(Firm's Registration No.-109273W)**

Raju P. Sardar

**Raju P. Sardar
(Proprietor)
(Membership No. 037845)**



**Place: Mumbai
Date: 12/11/2021**

UDIN - 21037845AAAAPN6930

THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the quarter and half year ended 30th September 2021.

(Amount in INR Lakhs)

		STANDALONE					
	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year to date figures for the current period ended	Year to date figures for the previous period ended	Year Ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	10,739.10	11,250.35	5,489.23	21,989.45	10,338.07	23,066.98
2	Other Income	21.33	34.93	213.11	56.26	249.01	362.21
3	Total Income (1 + 2)	10,760.43	11,285.28	5,702.34	22,045.71	10,587.08	23,429.19
4	Expenses :						
	(a) Cost of materials consumed	3,114.34	2,970.83	1,904.53	6,085.17	3,153.74	6,792.42
	(b) Purchases of stock-in-trade	934.27	838.18	275.30	1,772.45	530.99	1,155.45
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	71.65	342.21	(355.21)	413.86	(168.12)	(126.90)
	(d) Employee benefits expense	1,426.34	1,083.95	953.83	2,510.29	1,970.02	3,998.98
	(e) Finance Costs	205.16	266.91	370.75	472.07	670.21	1,271.21
	(f) Depreciation and amortisation expense	237.51	235.03	203.97	472.54	407.79	854.55
	(g) Other expenses	2,846.33	1,967.67	1,738.88	4,814.00	2,649.69	6,258.65
	Total expenses	8,835.60	7,704.78	5,092.05	16,540.38	9,214.32	20,204.36
5	Profit / (Loss) before exceptional items and tax (3 - 4)	1,924.83	3,580.50	610.29	5,505.33	1,372.76	3,224.83
6	Exceptional items	-	-	-	-	-	-
7	Profit / (Loss) before tax (5 - 6)	1,924.83	3,580.50	610.29	5,505.33	1,372.76	3,224.83
8	Tax expense :						
	(a) Current Tax	325.00	650.00	-	975.00	-	-
	(b) Deferred Tax	87.67	257.14	41.96	344.81	240.07	562.78
9	Profit / (Loss) for the period (7 - 8)	1,512.16	2,673.36	568.33	4,185.52	1,132.69	2,662.05
10	Other Comprehensive Income :						
	(a i) Items that will not be reclassified to Profit & Loss	(10.64)	(10.64)	(2.79)	(21.28)	(5.58)	(42.56)
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	2.68	2.68	0.71	5.36	1.41	10.71
	(b) Items that will be reclassified to Profit & Loss	-	-	-	-	-	-
11	Total Comprehensive Income for the period (9 + 10)	1,504.20	2,665.40	566.25	4,169.60	1,128.52	2,630.20
12	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	919.95	919.40	918.85	919.95	918.85	918.85
13	Other Equity (Excluding Revaluation Reserve)						14,204.20
14	Earnings per share :						
	(a) Basic	16.44	29.08	6.19	45.50	12.33	28.97
	(b) Diluted	16.40	29.03	6.18	45.41	12.32	28.96



THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the quarter and half year ended 30th September 2021.

(Amount in INR Lakhs)

Particulars		CONSOLIDATED					
		3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year to date figures for the current period ended	Year to date figures for the previous period ended	Year Ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	10,739.10	11,250.35	5,489.23	21,989.45	10,338.07	23,066.98
2	Other Income	21.33	34.93	213.11	56.26	249.01	362.21
3	Total Income (1 + 2)	10,760.43	11,285.28	5,702.34	22,045.71	10,587.08	23,429.19
4	Expenses :						
	(a) Cost of materials consumed	3,114.34	2,970.83	1,904.53	6,085.17	3,153.74	6,792.42
	(b) Purchases of stock-in-trade	934.27	838.18	275.30	1,772.45	530.99	1,155.45
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	71.65	342.21	(355.21)	413.86	(168.12)	(90.29)
	(d) Employee benefits expense	1,426.34	1,083.95	953.83	2,510.29	1,970.02	3,998.98
	(e) Finance Costs	205.20	266.91	370.75	472.11	670.23	1,271.25
	(f) Depreciation and amortisation expense	237.51	235.03	203.97	472.54	407.79	854.71
	(g) Other expenses	2,846.46	1,967.95	1,741.02	4,814.41	2,652.16	6,261.07
	Total expenses	8,835.77	7,705.06	5,094.19	16,540.83	9,216.81	20,243.59
5	Profit / (Loss) before exceptional items, share of Profit/(Loss) of associates and joint venture and tax (3 - 4)	1,924.66	3,580.22	608.15	5,504.88	1,370.27	3,185.60
6	Exceptional items	-	-	-	-	-	-
7	Profit / (Loss) before share of Profit / (Loss) of associates and joint venture and tax (5 - 6)	1,924.66	3,580.22	608.15	5,504.88	1,370.27	3,185.60
8	Add: Share of Profit / (Loss) of associates and a joint venture for the period	415.57	446.73	247.26	862.30	458.53	947.47
9	Profit / (Loss) before tax (7 + 8)	2,340.23	4,026.95	855.41	6,367.18	1,828.80	4,133.07
10	Tax expense :						
	(a) Current Tax	325.00	650.00	-	975.00	-	-
	(b) Deferred Tax	87.67	257.14	41.96	344.81	240.07	562.78
11	Profit / (Loss) for the period (9 - 10)	1,927.56	3,119.81	813.45	5,047.37	1,588.73	3,570.29
	Attributable to :						
	Equity holders of the Parent	1,927.57	3,119.81	813.45	5,047.38	1,588.73	3,570.30
	Non - Controlling interests	(0.01)	-	-	(0.01)	-	(0.01)
12	Other Comprehensive Income :						
	(a i) Items that will not be reclassified to Profit & Loss	(10.64)	(10.64)	(2.79)	(21.28)	(5.58)	(42.56)
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	2.68	2.68	0.71	5.36	1.41	10.71
	(a iii) Share of Other Comprehensive Income of Associates and Joint Ventures accounted using equity method	(0.18)	(0.18)	(0.00)	(0.36)	0.01	(0.71)
	(b) Items that will be reclassified to Profit & Loss	(0.89)	1.02	1.34	0.13	7.28	(8.15)
13	Total Comprehensive Income for the period (11 + 12)	1,918.53	3,112.69	812.71	5,031.22	1,591.85	3,529.58
	Attributable to :						
	Equity holders of the Parent	1,918.54	3,112.69	812.71	5,031.23	1,591.85	3,529.59
	Non - Controlling interests	(0.01)	-	-	(0.01)	-	(0.01)
14	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	919.95	919.40	918.85	919.95	918.85	918.85
15	Other Equity (Excluding Revaluation Reserve)						17,474.63
16	Earnings per share :						
	(a) Basic	20.95	33.93	8.85	54.87	17.29	38.86
	(b) Diluted	20.90	33.88	8.85	54.76	17.28	38.84



NOTES :

1 Statement of Assets and Liabilities :

(Amount in INR Lakhs)

Particulars	(STANDALONE)		(CONSOLIDATED)	
	As at 30th September, 2021	As at 31st March, 2021	As at 30th September, 2021	As at 31st March, 2021
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
ASSETS				
Non-Current Assets				
(a) Property, Plant and Equipment	12,858.35	12,974.53	12,858.94	12,975.00
(b) Capital Work-in-Progress	704.07	247.21	704.07	247.21
(c) Right-of-use Assets	162.22	214.37	162.22	214.37
(d) Intangible Assets	109.80	120.72	109.80	120.72
(e) Investments accounted for using the equity method	-	-	5,338.14	4,476.21
(f) Financial Assets				
(i) Investments	1,098.49	1,097.80	20.34	19.65
(ii) Other Financial Assets	31.13	28.13	31.13	28.13
(g) Other Non-Current Assets	490.43	485.77	490.43	485.77
	15,454.49	15,168.53	19,715.07	18,567.06
Current assets				
(a) Inventories	5,800.45	5,849.44	5,800.45	5,849.44
(b) Financial Assets				
(i) Trade Receivables	9,458.54	7,796.30	9,423.18	7,760.94
(ii) Cash and Cash Equivalents	1,567.26	1,900.47	1,568.54	1,901.80
(iii) Bank Balances Other than (ii) above	1,000.38	561.55	1,000.38	561.55
(iv) Other Financial Assets	538.71	531.97	538.71	531.97
(c) Other Current Assets	2,307.41	2,032.10	2,216.56	1,941.25
	20,672.75	18,671.83	20,547.82	18,546.95
TOTAL	36,127.24	33,840.36	40,262.89	37,114.01
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	919.95	918.85	919.95	918.85
(b) Other Equity	21,471.42	17,661.40	25,603.48	20,931.83
Equity attributable to equity holders of the parent	22,391.37	18,580.25	26,523.43	21,850.68
Non Controlling Interest	-	-	(0.07)	(0.06)
Total Equity	22,391.37	18,580.25	26,523.36	21,850.62
Liabilities				
Non Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	2,090.25	2,219.70	2,090.25	2,219.70
(ii) Lease Liabilities	81.50	118.25	81.50	118.25
(b) Provisions	-	-	-	-
(c) Deferred Tax Liabilities (Net)	434.29	94.83	434.29	94.83
	2,606.04	2,432.78	2,606.04	2,432.78
Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	4,429.63	6,295.94	4,429.63	6,295.94
(ii) Lease Liabilities	73.96	84.31	73.96	84.81
(iii) Trade Payables				
total outstanding dues of micro enterprises and small enterprises	18.06	37.94	18.06	37.94
total outstanding dues of creditors other than micro enterprises and small enterprises	4,111.09	3,040.26	4,112.03	3,041.25
(iv) Other Financial Liabilities	1,972.53	2,238.08	1,973.66	2,238.78
(b) Other Current Liabilities	49.51	981.50	51.10	983.09
(c) Provisions	150.05	149.30	150.05	149.30
(d) Current Tax Liabilities (Net)	325.00	-	325.00	-
	11,129.83	12,827.33	11,133.49	12,830.61
TOTAL	36,127.24	33,840.36	40,262.89	37,114.01



2 Statement of Cash Flows :

(Amount in INR Lakhs)

Particulars	(STANDALONE)		(CONSOLIDATED)	
	As at 30th September, 2021	As at 31st March, 2021	As at 30th September, 2021	As at 31st March, 2021
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
CASH FLOWS FROM OPERATING ACTIVITIES:				
Profit before tax	5,505.33	3,224.83	6,367.18	4,133.07
Adjustments for:				
Depreciation and amortisation expense	472.54	854.55	472.54	854.71
Loss on sale of property, plant and equipment	3.50	(2.26)	3.50	(2.26)
Changes in fair value of financial instruments at fair value through profit or loss	(0.70)	(1.88)	(0.70)	(1.88)
Dividend and interest income classified as investing cash flows	(13.65)	(234.01)	(13.65)	(234.01)
Finance costs	315.68	1,096.57	315.68	1,096.57
Share of (profit) Loss from joint ventures and associates	-	-	(861.94)	(946.75)
Change in operating assets and liabilities:				
(Increase)/Decrease in trade receivables	(1,662.24)	2,487.49	(1,662.24)	2,487.49
(Increase)/Decrease in inventories	48.99	(425.16)	48.99	(388.55)
Increase/(decrease) in trade payables	1,050.95	110.23	1,050.90	110.88
(Increase)/Decrease in other financial assets	(9.74)	(43.99)	(9.74)	(43.99)
(Increase)/decrease in other assets	(275.31)	(626.00)	(275.31)	(616.29)
Increase/(decrease) in provisions	(20.52)	(30.52)	(20.52)	(30.52)
(Increase)/Decrease in Other bank balance	(438.84)	(366.22)	(438.84)	(366.22)
Increase/(decrease) in other financial liabilities	(265.55)	(1,307.43)	(265.12)	(1,316.29)
Increase/(decrease) in other liabilities	(931.98)	953.62	(932.32)	953.85
Cash generated from operations	3,778.46	5,689.82	3,778.41	5,689.81
Less: (Income taxes paid)/ refund received (Net)	(654.66)	7.70	(654.66)	7.70
Net cash inflow from operating activities	3,123.80	5,697.52	3,123.75	5,697.51
CASH FLOWS FROM INVESTING ACTIVITIES:				
Payments for property, plant and equipment	(765.91)	(1,803.88)	(765.91)	(1,803.88)
Proceeds from sale of property, plant and equipment	12.26	4.75	12.26	4.75
Dividends received	-	192.80	-	192.80
Interest received	13.65	41.21	13.65	41.21
Net cash outflow from investing activities	(740.00)	(1,565.12)	(740.00)	(1,565.12)
CASH FLOWS FROM FINANCING ACTIVITIES:				
Proceeds from issues of equity shares	37.11	1.55	37.11	1.55
Receipts / (Repayment) of Current borrowings	(1,866.31)	(1,365.39)	(1,866.31)	(1,365.39)
Receipts / (Repayment) of non Current borrowings	(129.45)	122.52	(129.45)	122.52
Repayment of lease liabilities	(47.10)	(66.07)	(47.10)	(66.07)
Interest paid	(315.68)	(1,096.57)	(315.68)	(1,096.57)
Dividends paid	(395.58)	(160.79)	(395.58)	(160.79)
Net cash inflow (outflow) from financing activities	(2,717.01)	(2,564.74)	(2,717.01)	(2,564.74)
Net increase (decrease) in cash and cash equivalents	(333.21)	1,567.66	(333.26)	1,567.65
Cash and Cash Equivalents at the beginning of the financial year	1,900.47	332.81	1,901.80	334.15
Cash and Cash Equivalents at end of the year	1,567.26	1,900.47	1,568.54	1,901.80
Reconciliation of cash and cash equivalents as per the cash flow statement:				
Cash and cash equivalents as per above comprise of the following:				
Balances with banks				
- On current accounts	1,548.16	1,896.22	1,549.19	1,897.29
Cash on hand	19.10	4.25	19.35	4.51
Balances per statement of cash flows	1,567.26	1,900.47	1,568.54	1,901.80



- 3) The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its meeting held on November 12, 2021.
- 4) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 5) The paid-up equity share capital stands increased to ₹ 919.95 lakhs (91,99,540 equity shares of ₹ 10 each) upon allotment of 5,578 equity shares of ₹ 10 each pursuant to "ESOS 2012" during the quarter ended 30th September, 2021.
- 6) The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable segments as per Indian Accounting Standard (Ind AS) 108 - "Operating Segments".
- 7) The Company continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Company's financial results for the quarter and half year ended 30th September, 2021.
- 8) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable.

By Order of the Board
For THEMIS MEDICARE LTD



Dr. SACHIN PATEL
(Managing Director & CEO)
(DIN No. 00033353)

Place : Mumbai
Date : 12th November, 2021